Home » Topics » BioWorld Science

BioWorld Science
RSS

Results of phase IIb trial of topical PAC-14028, a TRPV1 antagonist, in atopic dermatitis

May 28, 2019

Optimization of quinazoline-based BET inhibitors for cancer and inflammatory diseases

May 28, 2019

OnKure begins new phase I trial of OKI-179 in solid tumors

May 27, 2019

Genmab initiates phase I/IIa safety study of GEN-1046 in malignant solid tumors

May 27, 2019

Phase III study of Lyrica in PGTC seizures fails to meet primary endpoint

May 27, 2019

PCI Biotech begins pivotal RELEASE study of fimaChem in inoperable bile duct cancer

May 27, 2019

Sensorion signs hearing loss research partnership framework agreement with Institut Pasteur

May 27, 2019

Alpine Immune Sciences divulges new fusion proteins

May 27, 2019

Nanjing CART Medical Technologies discloses CAR T cells for hematologic cancer

May 27, 2019

Zealand Pharma describes amylin and/or calcitonin receptor agonists

May 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
BioWorld
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and...